Search
  • mmahomed2

April 30, 2018

Valitor presented the its latest preclinical data at the 2018 Association for Research in Vision and Ophthalmology conference in Honolulu, HI. This report demonstrated a substantial increase in intravitreal half-life for our lead Anti-VEGF compound compared to the drugs that currently approved or in Phase III clinical trials. These results show the clear clinical benefits our products can offer for drugs that are used to treat ocular neovascular diseases.

0 views

© Valitor, Inc 2020

  • LinkedIn - White Circle